Welcome to our dedicated page for Replimune Group news (Ticker: REPL), a resource for investors and traders seeking the latest updates and insights on Replimune Group stock.
Replimune Group, Inc. (Nasdaq: REPL) generates frequent news as a clinical stage biotechnology company developing novel oncolytic immunotherapies based on its proprietary HSV‑1‑derived RPx platform. Headquartered in Woburn, Massachusetts and founded in 2015, the company focuses on product candidates such as RP1 (vusolimogene oderparepvec) and RP2, which are being studied across multiple difficult‑to‑treat cancers.
News related to Replimune commonly covers clinical trial updates from programs like IGNYTE, IGNYTE‑3, ARTACUS and REVEAL. These updates include data presentations at major medical meetings, such as the Society for Immunotherapy of Cancer (SITC) Annual Meeting and the European Society for Medical Oncology (ESMO) Congress, where the company has reported biomarker findings, response rates, durability of responses and safety data for RP1 plus nivolumab in advanced melanoma and non‑melanoma skin cancers.
Another major category of news involves regulatory milestones. Replimune has announced the FDA’s Complete Response Letter for the Biologics License Application (BLA) for RP1 in combination with nivolumab in advanced melanoma, subsequent Type A meetings with the FDA, and the agency’s acceptance of a BLA resubmission with a specified PDUFA target action date. These items are closely followed by investors and the oncology community because they reflect the evolving regulatory path for RP1.
Replimune’s news flow also includes corporate and financial updates, such as quarterly financial results, cash runway commentary, and equity‑based inducement grants to employees, as well as participation in investor conferences like the J.P. Morgan Healthcare Conference. Together, these announcements provide insight into the company’s operational progress, clinical development priorities and interactions with regulators.
Investors, clinicians and other stakeholders can use this news feed to track key developments around Replimune’s RPx platform, its lead programs in advanced melanoma and skin cancers, and the broader pipeline in metastatic uveal melanoma, hepatocellular carcinoma and biliary tract cancer.
Replimune Group Inc. (NASDAQ: REPL) announced the initial safety and efficacy data of its oncolytic immuno-gene therapy candidates, RP1 and RP2, during the Society for Immunotherapy of Cancer (SITC) virtual meeting. The Phase 1 trial of RP2 indicated promising results with 50% of patients showing ongoing partial responses. The RP1 trial also demonstrated positive outcomes, including a response rate of 87.5% in non-melanoma skin cancers. Both therapies exhibited manageable safety profiles, supporting further clinical study.
Replimune Group Inc. (Nasdaq: REPL) announces that CEO Philip Astley-Sparke will present at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 9:30 a.m. ET. Replimune is a biotechnology company based in Woburn, MA, specializing in developing oncolytic immuno-gene therapies through its Immulytic™ platform. This innovative approach aims to enhance the immune response to tumors and improve cancer treatment efficacy, particularly in conjunction with immune checkpoint blockade therapies.
Replimune Group, a biotechnology firm, announced a public offering of 2,826,088 shares of common stock at $23.00 per share, along with pre-funded warrants for 1,521,738 shares at $22.9999 each. The total gross proceeds are estimated at $100 million, excluding underwriting discounts. The offering is set to close on June 11, 2020, pending customary conditions. J.P. Morgan, SVB Leerink, and BMO Capital act as joint managers. This offering aims to fund ongoing development of Replimune's oncolytic immuno-gene therapies derived from its Immulytic platform.
Replimune Group, Inc. (Nasdaq: REPL) announced a proposed public offering of $80 million in common stock, alongside pre-funded warrants for certain investors. The offering includes a 30-day option for underwriters to purchase an additional $12 million in shares. The offering is subject to market conditions and customary closing criteria. J.P. Morgan Securities LLC, SVB Leerink LLC, and BMO Capital Markets Corp. are the joint book-running managers. All sales will be conducted under a previously filed shelf registration statement.
Replimune Group, Inc. (NASDAQ: REPL) reported fiscal Q4 and year-end financial results as of March 31, 2020. The net loss was $15.8 million for Q4 and $52.6 million for the fiscal year, an increase from $6.7 million and $30.8 million in the prior year. Cash and equivalents increased to $168.6 million from $134.8 million. Clinical updates revealed promising data for RP1 in treating cutaneous squamous cell carcinoma and melanoma. The firm is set to expand its clinical development into non-small cell lung cancer (NSCLC) and has completed a new manufacturing facility.
Summary not available.